Oxford BioMedica (LSE:OXB) Construction In Progress: £0.0 Mil (As of Dec. 2025)


LSE:OXB Oxford BioMedica PLC LSE:OXB
68 GF Score
Price £6.33
GF Value £5.36
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica Construction In Progress?

Oxford BioMedica LSE:OXB -0.16% 68 Construction In Progress is £0.0 Mil as of Dec. 2025. GuruFocus rates LSE:OXB with a GF Score™ of 68/100 and a GF Value™ of £5.36 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Oxford BioMedica Construction In Progress Historical Data

* Premium members only.

The historical data trend for Oxford BioMedica's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioMedica Construction In Progress Chart

Oxford BioMedica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Oxford BioMedica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:OXB
68GF Score
Oxford BioMedica PLC LSE:OXB
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oxford BioMedica Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of £0.0 Mil mean?
Oxford BioMedica (LSE:OXB) has a Construction In Progress of £0.0 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Oxford BioMedica and its competitors.
Is Oxford BioMedica's Construction In Progress too high?
Oxford BioMedica's current Construction In Progress is £0.0 Mil. Overall, Oxford BioMedica has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Construction In Progress compare to VRTX and REGN?
Oxford BioMedica's Construction In Progress of £0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Oxford BioMedica and its competitors. Oxford BioMedica's current Construction In Progress is £0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (LSE:OXB) is currently considered Modestly Overvalued. The stock's GF Value™ is £5.36, compared to a current price of £6.33 — trading 18.1% above its estimated fair value. The current Construction In Progress is £0.0 Mil. Oxford BioMedica's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Oxford BioMedica (LSE:OXB), the current Construction In Progress is £0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxford BioMedica (LSE:OXB) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of £6.33 is trading 18.1% above its estimated GF Value™ of £5.36. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for LSE:OXB:

  • Construction In Progress: £0.0 Mil
  • GF Value™: £5.36 vs. price of £6.33 (18.1% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the LSE:OXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxford BioMedica Business Description

Other Exchanges OXBDF:USAOXBl:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
68GF Score

Get the complete analysis for LSE:OXB

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£6.33
Price
£5.36
GF Value